We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron (REGN) Stock Moves -0.79%: What You Should Know
Read MoreHide Full Article
Regeneron (REGN - Free Report) closed at $556.75 in the latest trading session, marking a -0.79% move from the prior day. This change was narrower than the S&P 500's daily loss of 3.25%. At the same time, the Dow lost 2.42%, and the tech-heavy Nasdaq lost 0.48%.
Coming into today, shares of the biopharmaceutical company had lost 14.87% in the past month. In that same time, the Medical sector lost 1.96%, while the S&P 500 lost 5.62%.
Regeneron will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $9.94, down 61.47% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $2.77 billion, down 46% from the year-ago period.
REGN's full-year Zacks Consensus Estimates are calling for earnings of $42.38 per share and revenue of $11.57 billion. These results would represent year-over-year changes of -43.24% and -28.03%, respectively.
Any recent changes to analyst estimates for Regeneron should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.91% higher within the past month. Regeneron is holding a Zacks Rank of #3 (Hold) right now.
Valuation is also important, so investors should note that Regeneron has a Forward P/E ratio of 13.24 right now. Its industry sports an average Forward P/E of 20.16, so we one might conclude that Regeneron is trading at a discount comparatively.
Also, we should mention that REGN has a PEG ratio of 1.66. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.07 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 105, putting it in the top 42% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Regeneron (REGN) Stock Moves -0.79%: What You Should Know
Regeneron (REGN - Free Report) closed at $556.75 in the latest trading session, marking a -0.79% move from the prior day. This change was narrower than the S&P 500's daily loss of 3.25%. At the same time, the Dow lost 2.42%, and the tech-heavy Nasdaq lost 0.48%.
Coming into today, shares of the biopharmaceutical company had lost 14.87% in the past month. In that same time, the Medical sector lost 1.96%, while the S&P 500 lost 5.62%.
Regeneron will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $9.94, down 61.47% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $2.77 billion, down 46% from the year-ago period.
REGN's full-year Zacks Consensus Estimates are calling for earnings of $42.38 per share and revenue of $11.57 billion. These results would represent year-over-year changes of -43.24% and -28.03%, respectively.
Any recent changes to analyst estimates for Regeneron should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.91% higher within the past month. Regeneron is holding a Zacks Rank of #3 (Hold) right now.
Valuation is also important, so investors should note that Regeneron has a Forward P/E ratio of 13.24 right now. Its industry sports an average Forward P/E of 20.16, so we one might conclude that Regeneron is trading at a discount comparatively.
Also, we should mention that REGN has a PEG ratio of 1.66. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.07 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 105, putting it in the top 42% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.